July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
The frequency of adverse events in non-infectious uveitis patients treated with TNF inhibitors
Author Affiliations & Notes
  • Chisato Agata
    Ophthalmology, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
  • Toshikatsu Kaburaki
    Ophthalmology, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
  • Rie Tanaka
    Ophthalmology, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
  • Keiko Komae
    Ophthalmology, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
  • Hidetomo Izawa
    Ophthalmology, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
  • Hisae Nakahara
    Ophthalmology, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
  • Hidetoshi Kawashima
    Ophthalmology, Jichi Medical University Hospital, Shimotsuke-shi, Tochigi, Japan
  • Makoto Aihara
    Ophthalmology, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
  • Footnotes
    Commercial Relationships   Chisato Agata, None; Toshikatsu Kaburaki, None; Rie Tanaka, None; Keiko Komae, None; Hidetomo Izawa, None; Hisae Nakahara, None; Hidetoshi Kawashima, None; Makoto Aihara, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3523. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Chisato Agata, Toshikatsu Kaburaki, Rie Tanaka, Keiko Komae, Hidetomo Izawa, Hisae Nakahara, Hidetoshi Kawashima, Makoto Aihara; The frequency of adverse events in non-infectious uveitis patients treated with TNF inhibitors. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3523.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the frequency of adverse events in non-infectious uveitis patients treated with 2 TNF inhibitors: adalimumab (ADA) and infliximab (IFX).

Methods : Eighty non-infectious uveitis patients who presented to the uveitis clinic of The University of Tokyo Hospital and treated with TNF inhibitors during 2001 to 2018 were enrolled in this study; 27 non-infectious uveitis patients who treated with ADA (ADA group, 15 men and 12 women, mean follow-up periods of 25.6±25.7 months), and 53 Behcet’s disease patients who treated with IFX (IFX group, 40 men and 13 women, follow-up 72.6±47.1 months). The clinical records of the participants were retrospectively reviewed and the frequency of adverse events (AE) and serious adverse events (SAE) that could be associated with TNF inhibitors were analyzed.

Results : Sixteen AE (0.28 events/person/year) occurred in 10 patients (37%) in ADA group, whereas only 1 SAE (0.017 events/person/year, onset of polymyalgia rheumatica) were observed. The most common AE in ADA group were infections (8 events), followed by skin eruptions (3 events), infusion reaction (3 event), hepatic impairment (1 event), and polymyalgia rheumatica (1 event). On the other hand, 27 AE (0.084 events/person/year) occurred in 20 patients (41%) in IFX group and 6 SAE (0.019 events/person/year) were complicated. The most common AE in IFX group were infections (11 events), followed by infusion reaction (7 events), skin eruptions (5 events), neoplasm (2 events), elevation of serum creatine phosphokinase (1 event) and rhabdomyolysis (1 event). Six SAE in IFX group were caused by 2 miliary tuberculosis, 2 neoplasm, 1 rhabdomyolysis and 1 sinusitis. Attenuation of TNF inhibitors due to SAE or AE occurred in 1 patient (elevation of serum β-D-glucan) in ADA group and 6 patients in IFX group (2 miliary tuberculosis, 2 skin eruption, 1 rhabdomyolysis and 1 infusion reaction).

Conclusions : Our study showed that the frequency of AE in ADA group was higher compared to those in IFX group, whereas those of SAE was similar level. Further study with increased numbers of patients with longer follow-up periods must be necessary for confirming the difference of the frequency of AE and SAE between ADA and IFX therapy.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×